Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Honkoop, A. H.
Right arrow Articles by Pinedo, H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Honkoop, A. H.
Right arrow Articles by Pinedo, H. M.
The Oncologist, Vol. 4, No. 2, 106-111, April 1999
© 1999 AlphaMed Press

Prolonged Neoadjuvant Chemotherapy with GM-CSF in Locally Advanced Breast Cancer

Aafke H. Honkoopa, Sylvia A. Luykx-de Bakkera, Klaas Hoekmana, Sybren Meyerb, Otto W.M. Meyerc, Cees J. van Groeningena, Paul J. van Diestd, Epie Bovena, Elsken van der Walla, Giuseppe Giacconea, John Wagstaffa, Herbert M. Pinedoa

a Departments of Medical Oncology, b Surgery, c Radiotherapy and d Pathology, University Hospital, Vrije Universiteit, Amsterdam, The Netherlands

Correspondence: H.M. Pinedo, M.D., Ph.D., Department of Medical Oncology, University Hospital, Vrije Universiteit, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. Telephone: 31-20-444-4300; Fax: 31-20-444-4355; e-mail: oncol{at}azvu.nl

Background. Neoadjuvant chemotherapy improves survival in patients with locally advanced breast cancer (LABC). Usually three to four cycles of conventional-dose neoadjuvant chemotherapy are administered prior to local therapy, and another three cycles thereafter. In an attempt to improve results, we increased the dosages and applied GM-CSF, which, besides being a hematopoietic growth factor, has become increasingly known for its immunostimulatory effects, which might enhance the antitumor effect.

Methods. Forty-two patients with stage IIIA or IIIB breast cancer were treated with doxorubicin (A) (90 mg/m2) and cyclophosphamide (C) (1,000 mg/m2) at three-weekly intervals. In the second and fourth cycle a 10% dose reduction of both agents was applied. On the second day GM-CSF 250 µg/m2/day was started and given for 10 days. Initially, some patients were treated with <= four cycles, but as the study progressed and toxicity appeared tolerable, six cycles were given whenever possible. After the chemotherapy, patients underwent surgery and postoperative radiotherapy.

Results. The response rate for the whole group to AC was 98% (95% confidence interval 94%-100%), with a clinical complete response rate of 50% (95% confidence interval 35%-65%). Six patients had a pathological complete response. Median follow-up from the start of chemotherapy is 49 months (range 10-100). The disease-free survival (DFS) at three years is 57% and the overall survival (OS) at three years is 79%. There is a significant trend for improved DFS (p = 0.0000) and OS (p = 0.0002) with increasing number of cycles.

Conclusion. The results of the present study with neoadjuvant dose-intensive AC chemotherapy and GM-CSF compare favorably with previous studies in patients with LABC. This is most apparent in patients who received six cycles of neoadjuvant chemotherapy. We hypothesize that these encouraging results are probably related to the prolonged presence of the primary tumor, and to the long-term administration of GM-CSF with the primary tumor and axillary lymph nodes in situ. Therefore, a randomized study is warranted. We already initiated an international randomized trial in patients with LABC in order to answer two questions. First, does prolonged neoadjuvant chemotherapy result in an improved DFS and OS in comparison with the conventional approach, and secondly, what is the effect of GM-CSF in this approach in comparison with G-CSF?

Key Words. GM-CSF • Locally advanced breast cancer • Neoadjuvant chemotherapy




This article has been cited by other articles:


Home page
 The OncologistHome page
L. de la Cruz-Merino, E. Grande-Pulido, A. Albero-Tamarit, and M. E. Codes-Manuel de Villena
Cancer and Immune Response: Old and New Evidence for Future Challenges
Oncologist, December 1, 2008; 13(12): 1246 - 1254.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S. A. Bouwhuis, S. N. Markovic, M. T. McEvoy, and M. R. Pittelkow
Extracorporeal Photopheresis and Adjuvant Aerosolized Granulocyte-Macrophage Colony-Stimulating Factor for Sezary Syndrome
Mayo Clin. Proc., February 1, 2002; 77(2): 197 - 200.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Demaria, M. D. Volm, R. L. Shapiro, H. T. Yee, R. Oratz, S. C. Formenti, F. Muggia, and W. F. Symmans
Development of Tumor-infiltrating Lymphocytes in Breast Cancer after Neoadjuvant Paclitaxel Chemotherapy
Clin. Cancer Res., October 1, 2001; 7(10): 3025 - 3030.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H.M. Pinedo, T.D. de Gruijl, E. van der Wall, and J. Buter
Biological Concepts of Prolonged Neoadjuvant Treatment plus GM-CSF in Locally Advanced Tumors
Oncologist, December 1, 2000; 5(6): 497 - 500.
[Abstract] [Full Text]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 1999 by AlphaMed Press.
Advertisement